SEC Form S-8 filed by Milestone Pharmaceuticals Inc.
As filed with the Securities and Exchange Commission on March 13, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Milestone Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
Québec | Not applicable |
(State or other jurisdiction of incorporation or organization) |
(IRS employer identification number) |
1111 Dr. Frederik-Philips Boulevard, Suite 420 | |
Montréal, Québec CA | H4M 2X6 |
(Address of Principal Executive Offices) | (Zip Code) |
2019 Equity Incentive Plan
2019 Employee Share Purchase Plan
(Full titles of the plans)
Joseph Oliveto
Chief Executive Officer
Milestone Pharmaceuticals USA Inc.
6210 Ardrey Kell Road
Suite 650
Charlotte, NC 28277
(514) 336-0444
(Name, address, including zip code and telephone number, including area code, of agent for service)
Copies to:
Ryan S. Sansom
Peter Byrne
Cooley LLP
500 Boylston Street, 14th Floor
Boston, MA 02116
(617) 937-2300
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ¨ | Accelerated filer | ¨ |
Non-accelerated filer | x | Smaller reporting company | x |
Emerging growth company | ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
PART I
EXPLANATORY NOTE
This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Milestone Pharmaceuticals Inc. (the “Registrant”) for the purpose of registering (i) an additional 2,134,159 common shares issuable pursuant to the Milestone Pharmaceuticals Inc. 2019 Equity Incentive Plan (the “2019 EIP”) and (ii) an additional 487,837 common shares issuable pursuant to the Milestone Pharmaceuticals Inc. 2019 Employee Share Purchase Plan (the “2019 ESPP”), pursuant to the provisions of each plan which provide for annual automatic increases in the number of shares of common stock reserved for issuance under each respective plan.
In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents filed by the Registrant with the Securities and Exchange Commission (“SEC”) are incorporated by reference into this registration statement (other than information furnished under Item 2.02 or Item 7.01 of Form 8-K or other portions of documents filed with the SEC which are furnished, but not filed, pursuant to applicable rules promulgated by the SEC):
(a) | The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed on March 13, 2025 (the “Annual Report”); |
(b) | The description of Common Stock which is contained in a registration statement on Form 8-A filed on May 6, 2019 (File No. 001-38899) under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description. |
(c) | The Registrant’s Registration Statement on Form S-8, previously filed with the Commission on May 9, 2019 (File No. 333-231347), March 6, 2020 (File No. 333-236971), March 29, 2021 (File No. 333-254838), March 24, 2022 (File No. 333-263807), April 28, 2023 (File No. 333-271522) and November 12, 2024 (File No. 333-283160); and |
(d) | All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. |
Item 4. Description of Securities
See the description of the Registrant’s registered securities contained in Exhibit 4.5 to the Annual Report.
Item 8. Exhibits.
The exhibits to this Registration Statement are listed below:
* Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Montréal, Province of Québec, Canada on March 13, 2025.
Milestone Pharmaceuticals Inc. | ||
By: | /s/ Joseph Oliveto | |
Joseph Oliveto | ||
President and Chief Executive Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Joseph Oliveto and Amit Hasija, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.
Signature | Title | Date | ||
/s/ Joseph Oliveto | President, Chief Executive Officer and Director | |||
Joseph Oliveto | (Principal Executive Officer) | March 13, 2025 | ||
/s/ Amit Hasija | Chief Financial Officer | |||
Amit Hasija | (Principal Financial and Accounting Officer) | March 13, 2025 | ||
/s/ Stuart Duty | ||||
Stuart Duty | Director | March 13, 2025 | ||
/s/ Seth Fischer | ||||
Seth Fischer | Director | March 13, 2025 | ||
/s/ Lisa Giles | ||||
Lisa Giles | Director | March 13, 2025 | ||
/s/ Joseph Papa | ||||
Joseph Papa | Director | March 13, 2025 | ||
/s/ Andrew Saik | ||||
Andrew Saik | Director | March 13, 2025 | ||
/s/ Michael Tomsicek | ||||
Michael Tomsicek | Director | March 13, 2025 | ||
/s/ Robert Wills | ||||
Robert Wills | Director | March 13, 2025 |
SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT
Pursuant to the Securities Act, the undersigned, the duly authorized representative in the United States of Milestone Pharmaceuticals Inc. has signed this registration statement or amendment thereto on March 13, 2025.
MILESTONE PHARMACEUTICALS USA, INC. | ||
By: | /s/ Joseph Oliveto | |
Joseph Oliveto | ||
President and Chief Executive Officer |